AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of work with VAR2 Pharmaceuticals on the production of the company’s two antibody candidates targeting cancer-specific carbohydrate structures for cancer treatment.
The CDMO’s work included information transfer and master cell bank creation, method implementation, pilot-scale evaluations, preparation for large-scale manufacturing, regulatory documentation support for EMA or FDA guidelines and product stability studies.
‘We prioritize unparalleled support for every project we undertake, ensuring our clients receive the highest level of service and satisfaction. This project is a good example of how fast we are able to deliver results in close collaboration with our clients,’ said Dieter Kramer, General Manager of AGC Biologics Heidelberg.
VAR2 Pharmaceuticals proprietary antibody fragments –Vartumabs – have been shown to bind with high affinity and high specificity to onco-fetal Chondroitin Sulfate, a pan-cancer, tumor-specific glycosaminoglycan first identified by VAR2 Pharmaceuticals. The two antibody fragments produced in collaboration with AGC Biologics will be used in an upcoming, first-in-human, nuclear imaging microdosing study paving the way for efficacy trials with an ADC.
AGC Biologics runs multiple cGMP microbial production lines at its Heidelberg facility. The AGC Biologics Heidelberg site has produced biologics products for 40 years and has built a track record for navigating clients through the early clinical phases and into later stages, including commercial production.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is AGC Biologics Completes Production of Cancer-Specific Therapeutic Antibody Fragments with Var2 Pharmaceuticals.